January 2017

New Product - Invega Trinza

Invega Trinza (paliperidone palmitate) is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Invega Trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months. Since paliperdone is an active metabolite of risperidone, Invega Trinza is contraindicated in patients with a known hypersensitivity to risperidone. Invega Trinza is available as a suspension for injection containing either paliperidone 175 mg (0.875 mL, as paliperidone palmitate 273 mg) or 263 mg (1.315 mL, as paliperidone palmitate 410 mg) or 350 mg (1.75 mL, as paliperidone palmitate 546 mg) or 525 mg (2.625 mL, as paliperidone palmitate 819 mg) in a prefilled syringe with plunger stopper and 2 safety needles in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629